Influence of gemfibrozil on high-density lipoproteins.
In animal studies, gemfibrozil markedly elevates high-density lipoprotein (HDL) cholesterol levels. In humans with primary hyperlipoproteinemia and lipoprotein phenotypes IIA, IIB and IV, gemfibrozil, 1,200 mg/day, was associated with a 25%, 20% and 17% increase in HDL cholesterol, respectively. Gemfibrozil also substantially increased the ratio of HDL to total cholesterol, reflecting both an increase in HDL cholesterol and a decrease in very low density lipoprotein cholesterol and low-density lipoprotein cholesterol. Compared with a placebo in subjects with types IIA, IIB and IV lipoprotein phenotypes, therapy with gemfibrozil led to an increase of 33%, 34% and 23%, respectively, in the ratio of HDL cholesterol to total cholesterol. With gemfibrozil therapy, about 80% of subjects with hypertriglyceridemia had a reduction in triglycerides of 35% or a return to normal levels; 50% of subjects with hypercholesterolemia had a cholesterol reduction of 20% or a return to normal levels.
D000818:Animals; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D015248:Gemfibrozil; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000097:blood*; D010421:Pentanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D014631:Valerates / Q000494:pharmacology*
D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D010421:Pentanoic Acids; D014631:Valerates; D002784:Cholesterol; D015248:Gemfibrozil